Literature DB >> 11113012

Variants of trophic factors and expression of cardiac hypertrophy in patients with hypertrophic cardiomyopathy.

R Patel1, D S Lim, D Reddy, S F Nagueh, S Lutucuta, M J Sole, W A Zoghbi, M A Quiñones, R Roberts, A J Marian.   

Abstract

Patients with hypertrophic cardiomyopathy (HCM) exhibit variable expression of left ventricular hypertrophy (LVH), a major determinant of mortality and morbidity, which is partly due to the diversity of causal mutations, genetic background (modifier genes), and probably environmental factors. We determined association of functional variants of tumor necrosis factor (TNF)- alpha, interleukin-6 (IL6), insulin-like growth factor-2 (IGF2), transforming growth factor- beta 1 (TGFB1), and aldosterone synthase (CYP11B2) genes, all previously implicated in cardiac hypertrophy, with the severity of LVH in patients with HCM. Two-dimensional echocardiography was performed and demographic variables were recorded in 142 genetically independent patients. Indices of LVH including interventricular septal thickness (IVST), left ventricular mass index (LVMI), and LVH score were measured/calculated. TNF-alpha-308G/A, IL6-174G/C, IGF2 820G/A, TGFB1-509C/T, and CYP11B2-344T/C genotypes were determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Genotypes were identified by the presence of specific electrophoretic patterns and their distributions were according to the Hardy-Weinberg equilibrium. Demographic variables were not significantly different among the genotypes. Subjects with the AA genotype of TNF-alpha (n=8) were approximately 13 years younger at the time of clinical diagnosis. Despite a younger age, they had a greater mean LVMI than those with the GG (n=94) or GA (n=33) genotypes (191.8+/-59.5 v 139.1+/-47.3 v 132.1+/-34.3, respectively, P=0.004). TNF-alpha-308G/A genotypes accounted for 6.0% of variability of LVMI (P=0.002). Mean IVST, LVEDD, and LVH score were not significantly different. Variants of IL6, IGF2, TGFB1, and CYP11B2 were not associated with indices of LVH. The uncommon allele of TNF-alpha-308G/A polymorphism, known to produce more TNF- alpha, was associated with greater LVMI and clinical diagnosis at a younger age in patients with HCM. Functional variants of other trophic factors, previously implicated in cardiac hypertrophy, were not associated with the indices of LVH. These results suggest that TNF-alpha is a modifier gene for HCM. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11113012     DOI: 10.1006/jmcc.2000.1267

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  18 in total

Review 1.  Modifier genes for hypertrophic cardiomyopathy.

Authors:  A J Marian
Journal:  Curr Opin Cardiol       Date:  2002-05       Impact factor: 2.161

Review 2.  The molecular genetic basis for hypertrophic cardiomyopathy.

Authors:  A J Marian; R Roberts
Journal:  J Mol Cell Cardiol       Date:  2001-04       Impact factor: 5.000

Review 3.  Hypertrophic cardiomyopathy: from genetics to treatment.

Authors:  Ali J Marian
Journal:  Eur J Clin Invest       Date:  2010-04       Impact factor: 4.686

Review 4.  Contemporary treatment of hypertrophic cardiomyopathy.

Authors:  Ali J Marian
Journal:  Tex Heart Inst J       Date:  2009

5.  TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II.

Authors:  Jo El J Schultz; Sandra A Witt; Betty J Glascock; Michelle L Nieman; Peter J Reiser; Stacey L Nix; Thomas R Kimball; Thomas Doetschman
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

6.  Systemic inflammation is associated with myocardial fibrosis, diastolic dysfunction, and cardiac hypertrophy in patients with hypertrophic cardiomyopathy.

Authors:  Lu Fang; Andris H Ellims; Anna L Beale; Andrew J Taylor; Andrew Murphy; Anthony M Dart
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

7.  Mutations of the beta myosin heavy chain gene in hypertrophic cardiomyopathy: critical functional sites determine prognosis.

Authors:  A Woo; H Rakowski; J C Liew; M-S Zhao; C-C Liew; T G Parker; M Zeller; E D Wigle; M J Sole
Journal:  Heart       Date:  2003-10       Impact factor: 5.994

8.  Hypertrophy Regression With N-Acetylcysteine in Hypertrophic Cardiomyopathy (HALT-HCM): A Randomized, Placebo-Controlled, Double-Blind Pilot Study.

Authors:  Ali J Marian; Yanli Tan; Lili Li; Jeffrey Chang; Petros Syrris; Manouchehr Hessabi; Mohammad H Rahbar; James T Willerson; Benjamin Y Cheong; Chia-Ying Liu; Neal S Kleiman; David A Bluemke; Sherif F Nagueh
Journal:  Circ Res       Date:  2018-03-14       Impact factor: 17.367

Review 9.  Intramyocardial fibroblast myocyte communication.

Authors:  Rahul Kakkar; Richard T Lee
Journal:  Circ Res       Date:  2010-01-08       Impact factor: 17.367

10.  CMR findings in patients with hypertrophic cardiomyopathy and atrial fibrillation.

Authors:  Theano Papavassiliu; Tjeerd Germans; Stephan Flüchter; Christina Doesch; Anton Suriyakamar; Dariusch Haghi; Tim Süselbeck; Christian Wolpert; Dietmar Dinter; Stefan O Schoenberg; Albert C van Rossum; Martin Borggrefe
Journal:  J Cardiovasc Magn Reson       Date:  2009-09-09       Impact factor: 5.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.